Faruqi & Faruqi Urges UniQure Investors to Act Before Class Action Deadline Approaches

Shareholder Alert: Important Deadline for UniQure Investors

Faruqi & Faruqi, LLP, a prominent national securities law firm, has issued an alert to shareholders of UniQure N.V. (NASDAQ: QURE), emphasizing the urgent need for affected investors to consider their legal options before the window closes on April 13, 2026. This announcement comes on the heels of significant revelations regarding UniQure’s compliance with federal securities regulations, which may have adversely impacted the company's investors.

Investigative Actions by Faruqi & Faruqi

The firm is currently investigating possible claims against UniQure for purported violations of federal securities laws. According to the firm, investors who acquired UniQure securities between September 24, 2025, and October 31, 2025, may have grounds to pursue legal recourse. Notably, the investigation is spurred by allegations that UniQure and its executives misrepresented critical information regarding regulatory approvals tied to the company's pivotal studies for its product pipelines.

James (Josh) Wilson, a Senior Partner at Faruqi & Faruqi, has actively encouraged investors suffering losses from their investments in UniQure to reach out directly for consultations. Interested parties can call his office at 877-247-4292 or 212-983-9330 (Ext. 1310) for further details and guidance.

Alleged Misrepresentations by UniQure

The issues surrounding UniQure intensified following disclosures made on November 3, 2025. The company acknowledged that the FDA no longer agreed with its prior assertions regarding the adequacy of data from earlier Phase I/II studies to support a Biologics License Application (BLA). Specifically, the design of UniQure's pivotal study had reportedly not received full approval from the FDA, raising substantial questions about the validity of prior statements made by the company.

These disclosures led to a dramatic decline in UniQure's stock price, plunging over 49%—from $67.69 to $34.29 on a single day, reflecting the fallout from investors’ negative reactions to the news. The sudden drop highlighted the disconnect between the company’s prior communications regarding the product approval timeline and the unfortunate realities of regulatory scrutiny.

What Investors Should Know

For shareholders contemplating their next steps, it's essential to identify the timeline for filing claims and to understand the process of becoming a lead plaintiff in a class action lawsuit. The lead plaintiff status is significant as it represents the individual with the most substantial financial stake and is responsible for overseeing and directing legal action on behalf of affected shareholders.

Moreover, individuals who hold critical information tied to UniQure's practices—be they whistleblowers, former employees, or current investors—are encouraged to come forward to assist the ongoing investigation by contacting Faruqi & Faruqi directly.

As the April 13, 2026, deadline approaches, the time for action is limited. Therefore, investors are urged to seek legal counsel to better navigate this complex situation and secure their potential claims for restitution.

How to Get Involved

To learn more about the particulars of the UniQure class action and how to participate, shareholders can visit the dedicated section on Faruqi & Faruqi's website at www.faruqilaw.com/QURE, where updated information will be provided as the case progresses.

This alert serves as a critical reminder for all investors involved with UniQure to stay informed and proactive regarding their rights, particularly as legal landscapes can shift rapidly. Faruqi & Faruqi remains committed to advocating for investors and recovering losses wherever possible.

For any further queries or legal assistance concerning the UniQure case, please don't hesitate to contact Faruqi & Faruqi without delay.